Drugs / Glyburide
Glyburide
also known as
glibenclamide · Amglidia · DiaBeta · BIIB093 · CALABREN · CIRARA · DAONIL · DIABETAMIDE 2.5 · +21 more
Small molecule targets ABCC8
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Amglidia | — | 2018-05-24 | europa.eu ↗ |
| Approved | US (FDA) | DIABETA | — | 1984-05-01 | fda.gov ↗ |
Trials 58
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 113 trials · 2 met primary | ||||||
| Phase 1 | NCT07221799 | Sep 2026 → Sep 2028 expected | multiple sclerosis, neuropathy, painful | University of Maryland, Baltimore | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05426681 | Jul 2022 → May 2027 expected | spinal cord injury | Francis Farhadi | Recruiting | No outcome recorded |
| Phase 1 | NCT04859452 | May → Jul 2021 | — | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03856970 | Mar → Jun 2019 | — | Ironwood Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02128022 | Jul 2014 → Mar 2016 | coronary artery disorder | Papworth Hospital NHS Foundation Trust | Completed | No outcome recorded |
| Phase 1 | NCT01132703 | Jan → May 2010 | stroke disorder, traumatic brain injury | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT01733108 | Jul → Sep 2008 | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 1 | NCT02183428 | May → Jul 2008 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00388986 | Oct 2006 → Jul 2007 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT00865436 | Apr 2004 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00836472 | Apr 2003 | — | Teva Pharmaceuticals USA | Completed | Met primary |
| Phase 1 | NCT00835991 | Feb 2003 | — | Teva Pharmaceuticals USA | Completed | Met primary |
| Phase 1 | NCT00865241 | Nov 2002 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT05148403 | Oct 2021 → Oct 2022 | traumatic brain injury | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT02460874 | Aug 2017 → May 2021 | brain edema, metastatic malignant neoplasm in the brain | University of Alabama at Birmingham | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT02524379 | Feb 2017 → Feb 2021 | spinal cord injury | Ohio State University | Terminated | No outcome recorded |
| Phase 1/2 | NCT01268683 | May 2011 → Jun 2012 | ischemic stroke | Remedy Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 26 trials · 1 missed | ||||||
| Phase 2 | NCT05687500 | May 2023 → Oct 2025 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT02830048 | Jul 2016 → Mar 2017 | type 2 diabetes mellitus | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT01794182 | Jun 2013 → Apr 2016 | ischemic stroke | Remedy Pharmaceuticals, Inc. | Completed | Missed primary |
| Phase 2 | NCT01454154 | Dec 2011 → Feb 2015 | traumatic brain injury | Remedy Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00610038 | Jul 2006 → Aug 2010 | diabetes mellitus | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT00451620 | Nov 2003 → Sep 2011 | type 2 diabetes mellitus | University of British Columbia | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00515801 | Jun 2007 → ? | type 1 diabetes mellitus | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 39 trials · 1 met primary · 2 missed | ||||||
| Phase 3 | NCT02375828 | Mar 2015 → Mar 2016 | neonatal diabetes mellitus | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT01731431 | May 2012 → Mar 2017 | gestational diabetes | Assistance Publique - Hôpitaux de Paris | Completed | Missed primary |
| Phase 3 | NCT01215331 | Aug 2010 → Apr 2014 | gestational diabetes | University of Sherbrooke | Completed | No outcome recorded |
| Phase 3 | NCT00267683 | Dec 2005 → Apr 2006 | type 2 diabetes mellitus | Novo Nordisk A/S | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00255541 | Sep 2004 → Dec 2006 | type 2 diabetes mellitus | AstraZeneca | Terminated | No outcome recorded |
| Phase 3 | NCT00035542 | Dec 2001 → Oct 2003 | type 2 diabetes mellitus | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00046462 | Nov 2001 → Nov 2004 | type 2 diabetes mellitus | Sanofi | Completed | Missed primary |
| Phase 3 | NCT00379769 | Apr 2001 → Dec 2008 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00279045 | Jan 2000 → Jun 2006 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | Met primary |
| Phase 416 trials · 1 met primary · 2 missed | ||||||
| Phase 4 | NCT07802561 | Apr → Oct 2026 expected | gestational diabetes | Nishtar Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT05137678 | Oct 2021 → Oct 2022 | subarachnoid hemorrhage | Beijing Tiantan Hospital | Unknown | Missed primary |
| Phase 4 | NCT02624830 | Feb 2019 → Feb 2020 | permanent neonatal diabetes mellitus | Haukeland University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03569540 | Jul 2018 → Jul 2019 | acquired aneurysmal subarachnoid hemorrhage | University of Sao Paulo General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04239586 | Apr 2017 → Apr 2022 | maturity-onset diabetes of the young type 1, maturity-onset diabetes of the young type 3, type 1 diabetes mellitus | Haukeland University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03089333 | Jul 2016 → Oct 2017 | hypertensive disorder, obesity disorder, proteinuria, type 2 diabetes mellitus | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 4 | NCT02624817 | Dec 2015 → Aug 2016 | permanent neonatal diabetes mellitus | Haukeland University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01867502 | Apr 2014 → Aug 2015 | hyperglycemia, hypoglycemia, type 2 diabetes mellitus | Hospital de Clinicas de Porto Alegre | Unknown | No outcome recorded |
| Phase 4 | NCT01947699 | Sep 2013 → Sep 2014 | gestational diabetes | University of Pittsburgh | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01456650 | Mar 2011 → Nov 2012 | type 2 diabetes mellitus | National Institute of Medical Sciences and Nutrition Salvador Zubiran | Completed | Met primary |
| Phase 4 | NCT00700856 | Sep 2008 → Dec 2018 | cardiovascular disorder, type 2 diabetes mellitus | Italian Society of Diabetology | Unknown | Missed primary |
| Phase 4 | NCT00472875 | May 2007 → ? | type 1 diabetes mellitus | King's College Hospital NHS Trust | Unknown | No outcome recorded |
| Phase 4 | NCT00417729 | Jan 2007 → Jan 2009 | type 2 diabetes mellitus | Taichung Veterans General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00160485 | Jun 2004 → Jun 2009 | gestational diabetes | Tripler Army Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT01698931 | Apr 2002 → Mar 2003 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00035568 | Feb 2002 → Jun 2003 | type 2 diabetes mellitus | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase not applicable9 trials · 1 missed | ||||||
| — | NCT06907472 | Sep 2025 → Jun 2026 overdue | type 2 diabetes mellitus | University of Abuja | Active not recruiting | No outcome recorded |
| — | NCT06589141 | Jan → Dec 2025 overdue | gestational diabetes | Assiut University | Not yet recruiting | No outcome recorded |
| — | NCT03741530 | Dec 2018 → Sep 2020 | intracerebral hemorrhage | Xijing Hospital | Completed | Missed primary |
| — | NCT02255006 | May → Oct 2014 | — | Kyunghee University Medical Center | Unknown | No outcome recorded |
| — | NCT00696982 | Jun 2008 → Jun 2009 | arteriosclerosis disorder, diabetes mellitus | Assaf-Harofeh Medical Center | Unknown | No outcome recorded |
| — | NCT00486187 | Apr 2006 → Jun 2009 | type 2 diabetes mellitus | Dr. Milan Gupta | Completed | No outcome recorded |
| — | NCT00371306 | Sep 2002 → Sep 2008 | gestational diabetes, type 2 diabetes mellitus | Regional Obstetrical Consultants | Unknown | No outcome recorded |
| — | NCT00608179 | Aug 2002 → Sep 2004 | type 2 diabetes mellitus | Vanderbilt University | Completed | No outcome recorded |
| — | NCT00549874 | Feb 2002 → Nov 2006 | type 2 diabetes mellitus | University of Michigan | Completed | No outcome recorded |
| Comparator or background therapy46 trials | ||||||
| Phase 0 | NCT02726490 Comparator | Jul 2016 → Aug 2018 | gestational diabetes | Texas Tech University Health Sciences Center, El Paso | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02815787 Comparator | Mar → Jul 2014 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01716338 Comparator | Jan 2013 → May 2014 | — | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01319734 Comparator | Feb 2011 → Dec 2015 | type 2 diabetes mellitus | Al-Neelain University | Unknown | No outcome recorded |
| Phase 1 | NCT00935363 Comparator | Feb → Mar 2010 | — | University of California, San Francisco | Withdrawn | No outcome recorded |
| Phase 1 | NCT00864734 Comparator | Nov 2002 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01329016 Comparator | Jul 2011 → Feb 2015 | gestational diabetes | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
| Phase 1/2 | NCT01145534 Comparator | Jan → Aug 2009 | type 2 diabetes mellitus | Federal University of Paraíba | Completed | No outcome recorded |
| Phase 2 | NCT01029795 Comparator | Feb → Jun 2010 | type 2 diabetes mellitus | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 2/3 | NCT03284463 Comparator | Jan 2018 → Aug 2022 | stroke disorder | Nanfang Hospital, Southern Medical University | Completed | No outcome recorded |
| Phase 3 | NCT05688332 Comparator | Aug → Dec 2023 | type 2 diabetes mellitus | University of Zambia | Unknown | No outcome recorded |
| Phase 3 | NCT02080377 Comparator | Jul 2014 → Oct 2015 | gestational diabetes | University of Edinburgh | Completed | No outcome recorded |
| Phase 3 | NCT01584232 Background | Apr 2012 → Jul 2013 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT01822548 Comparator | Oct 2010 → Dec 2014 | type 2 diabetes mellitus | Azienda Ospedaliero-Universitaria di Parma | Completed | Met primary |
| Phase 3 | NCT01242215 Background | Sep 2010 → Apr 2012 | type 2 diabetes mellitus | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 3 | NCT01340768 Comparator | Jun 2010 → Sep 2011 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT00393718 Comparator | Nov 2006 → Nov 2007 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 3 | NCT00395746 Background | Oct 2006 → Oct 2007 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 3 | NCT00286468 Background | Apr 2006 → Jun 2007 | diabetes mellitus | Takeda | Completed | Met primary |
| Phase 3 | NCT00313313 Comparator | Apr 2006 → Sep 2007 | diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00251940 Background | Jul 2004 → Mar 2006 | type 2 diabetes mellitus | AstraZeneca | Terminated | No outcome recorded |
| Phase 3 | NCT00759720 Comparator | Nov 2003 → Dec 2004 | diabetes mellitus | Takeda | Terminated | No outcome recorded |
| Phase 3 | NCT00521742 Comparator | Mar 2001 → Jan 2003 | type 2 diabetes mellitus | Takeda | Completed | Missed primary |
| Phase 3 | NCT00521820 Comparator | Jun 2000 → Oct 2003 | type 2 diabetes mellitus | Takeda | Terminated | Missed primary |
| Phase 4 | NCT03029702 Comparator | Feb 2018 → Aug 2023 | gestational diabetes | Maisa N. Feghali, MD | Completed | No outcome recorded |
| Phase 4 | NCT03078725 Comparator | Jun 2017 → Mar 2018 | gestational diabetes | The University of Texas Health Science Center, Houston | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02919345 Comparator | Jan 2017 → Dec 2018 | carotid artery disorder, coronary artery disorder, type 2 diabetes mellitus | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 4 | NCT02318693 Comparator | Feb → Dec 2015 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 4 | NCT02201602 Comparator | Aug 2014 → Jun 2016 | type 2 diabetes mellitus | Khoo Teck Puat Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02091336 Comparator | Jan → Dec 2014 | gestational diabetes | Hospital de Clinicas de Porto Alegre | Unknown | No outcome recorded |
| Phase 4 | NCT02145611 Comparator | Jul 2013 → May 2016 | hypertensive disorder, type 2 diabetes mellitus | Dr. José Fernando Vilela-Martin MD PhD | Completed | No outcome recorded |
| Phase 4 | NCT01563120 Comparator | Jan 2012 → Jun 2014 | gestational diabetes | HaEmek Medical Center, Israel | Completed | No outcome recorded |
| Phase 4 | NCT01131182 Comparator | Jun → Nov 2010 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 4 | NCT00770835 Comparator | Mar 2009 → May 2011 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 4 | NCT01107717 Comparator | Jan 2009 → Feb 2023 | type 2 diabetes mellitus | The University of Texas Health Science Center at San Antonio | Completed | Met primary |
| Phase 4 | NCT00744965 Comparator | Sep 2008 → Jan 2013 | gestational diabetes | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00347100 Comparator | Jun 2006 → May 2008 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT01045590 Comparator | Dec 2003 → Feb 2006 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00123643 Comparator | May 2003 → Dec 2005 | type 2 diabetes mellitus | St. Paul Heart Clinic | Completed | No outcome recorded |
| Phase 4 | NCT01605773 Comparator | Nov 2001 → Mar 2003 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00494312 Comparator | Oct 2000 → Jun 2005 | liver disorder, type 2 diabetes mellitus | Takeda | Completed | Missed primary |
| — | NCT04960657 Comparator | Oct 2020 → Mar 2021 | migraine disorder | Danish Headache Center | Completed | No outcome recorded |
| — | NCT04231617 Comparator | Jan → Aug 2020 | headache disorder | Danish Headache Center | Completed | No outcome recorded |
| — | NCT00232583 Comparator | Nov 2003 → Dec 2011 | type 2 diabetes mellitus | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| — | NCT00965991 Comparator | Jul 2003 → May 2008 | gestational diabetes | University of New Mexico | Completed | No outcome recorded |
| — | NCT00194896 Comparator | Feb 2000 → Sep 2008 | type 2 diabetes mellitus | University of Washington | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2005-01-28 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Approval Of Glyburide/Metformin Hcl Tablets tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the company's ANDA for Glyburide and Metformin HCl Tablets, 1.25 mg/250 mg, 2.5 mg/500 mg and 5 mg/500 mg. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-09-04 | Biogen | Biogen Enrolls First Patient in Global Phase 3 Study of BIIB093 (IV Glibenclamide) for Large Hemispheric Infarction biogen.com ↗ |
| 2017-05-15 | Biogen | Biogen Acquires Remedy Pharmaceuticals’ CIRARA™ for Large Hemispheric Stroke biogen.com ↗ |
| 2005-01-28 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval Of Glyburide/Metformin Hcl Tablets tevapharm.com ↗ |
Evidence & citations 34 cited values
Every value below carries the sentence it was read from. 109 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | glyburide | “Subjects taking metformin before randomization were randomly assigned to the addition of glyburide (2.5 mg BID titrated to 5 mg BID if baseline A1C ≥7.5% and ≤8.0%, or 5 mg BID...” NCT00486187 ↗58“Glyburide is an oral antidiabetic agent of the sulfonylurea class, and impacts glycemic control by stimulating the pancreas to release insulin, an effect that is dependent upon...” NCT00494312 ↗ “Glibenclamide (US adopted name, glyburide), a long-acting sulfonylurea, shows promising result in treating AIS from both preclinical and clinical studies.” PMID 32527232 ↗ Jun 2020 “Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test.” NCT00451620 ↗ |
| Known as | Amglidia | “CONCLUSION: The glibenclamide oral suspension Amglidia, the first anti-diabetic drug specifically developed for pediatric patients, is acceptable, effective, and safe in...” PMID 30684309 ↗ Feb 20191“Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk” NCT05687500 ↗ |
| Known as | BIIB093 | “intravenous (IV) glibenclamide (BIIB093; glyburide) treatment was the only independent predictor of 3-month mRS in multivariate regression analysis” PMID 31787498 ↗ Nov 2019 |
| Known as | CALABREN | ChEMBL registry synonym — accepted as the source's own label CHEMBL472 ↗ |
| Known as | CIRARA | ChEMBL registry synonym — accepted as the source's own label CHEMBL472 ↗ |
| Known as | DAONIL | ChEMBL registry synonym — accepted as the source's own label CHEMBL472 ↗ |
| Known as | DiaBeta | “Glyburide (Dia-Beta) 10 mg oral dose during protocol, given once during each protocol.” NCT00608179 ↗1“oral Glyburide (DiaBeta) in Patients With Acute Traumatic Spinal Cord Injury” NCT02524379 ↗ |
| Known as | DIABETAMIDE 2.5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL472 ↗ |
| Known as | DIABETAMIDE 5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL472 ↗ |
| Known as | Euglucon | “8 healthy volunteers are administered 5 mg of glibenclamide (Euglucon, Roche Pharma) 3 hour before FMD measurement.” NCT02255006 ↗ |
| Known as | GLIBENCLAMIDA | ChEMBL registry synonym — accepted as the source's own label CHEMBL472 ↗ |
| Known as | glibenclamide | “Step 1: Metformin 500 mg daily Step 2: Metformin 1000 mg daily Step 3: Metformin 1000 mg twice daily Step 4: Metformin 1000 mg twice daily + glibenclamide 5 mg daily Step 5:...” NCT06907472 ↗46“The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or miconizied equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4...” NCT00379769 ↗ “Patients in the glibenclamide + rosiglitazone treatment group who have FPG \< 270mg/dL after the glibenclamide 5mg om run-in will receive glibenclamide 5mg om + rosiglitazone 4mg om.” NCT01045590 ↗ “Sulfonylurea tablets (glibenclamide, other forms of sulfonylureas) were administered at the time of intervention (before November 1, 2006).” NCT02624830 ↗ “Sulfonylurea (glibenclamide, glimepiride, or gliclazide) administered orally daily over the Ramadan period as per physician's prescription” NCT01131182 ↗ “OAMs included sulfonylureas (SU; glibenclamide, gliclazide, or glimepiride) and/or biguanides (BG; metformin or buformin).” NCT01584232 ↗ “each added to SU monotherapy (glibenclamide, glicazide or glimeprimide) in a 24-week, double-blind, parallel-group trial.” PMID 20380655 ↗ Apr 2010 “a sulfonylurea (5-15 mg glibenclamide, 2-6 mg glimepiride, or 30-120 mg gliclazide, in accordance with local practice)” PMID 28917544 ↗ Sep 2017 “8 healthy volunteers are administered 5 mg of glibenclamide (Euglucon, Roche Pharma) 3 hour before FMD measurement.” NCT02255006 ↗ “Glibenclamide was introduced in increasing doses to investigate whether sulfonylurea could replace insulin.” PMID 15448106 ↗ Oct 2004 “in which 2097 patients with type 2 diabetes received either pioglitazone or glibenclamide (glyburide).” PMID 19670918 ↗ 2009 |
| Known as | GLIBENCLAMIDUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL472 ↗ |
| Known as | GLIKEN | ChEMBL registry synonym — accepted as the source's own label CHEMBL472 ↗ |
| Known as | Glinbentek | “The aim of this study is then to determine the tolerance and acceptability of an oral solution of glibenclamide (Glinbentek) developed and dedicated to pediatric patients with...” NCT02375828 ↗ |
| Known as | glybenclamide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01563120 ↗ |
| Known as | GLYBURIDE (GLIBENCLAMIDE) | ChEMBL registry synonym — accepted as the source's own label CHEMBL472 ↗ |
| Known as | GLYBURIDE (MICRONIZED) | ChEMBL registry synonym — accepted as the source's own label CHEMBL472 ↗ |
| Known as | GLYBURIDE COMPONENT OF GLUCOVANCE | ChEMBL registry synonym — accepted as the source's own label CHEMBL472 ↗ |
| Known as | GLYBURIDE10238-21-8 | ChEMBL registry synonym — accepted as the source's own label CHEMBL472 ↗ |
| Known as | GLYNASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL472 ↗ |
| Known as | HB 419 | ChEMBL registry synonym — accepted as the source's own label CHEMBL472 ↗ |
| Known as | LEDERGLIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL472 ↗ |
| Known as | LIBANIL | ChEMBL registry synonym — accepted as the source's own label CHEMBL472 ↗ |
| Known as | MALIX | ChEMBL registry synonym — accepted as the source's own label CHEMBL472 ↗ |
| Known as | MICRONASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL472 ↗ |
| Known as | NSC-759618 | ChEMBL registry synonym — accepted as the source's own label CHEMBL472 ↗ |
| Known as | SEMI-DAONIL | ChEMBL registry synonym — accepted as the source's own label CHEMBL472 ↗ |
| Known as | U-26,45 | ChEMBL registry synonym — accepted as the source's own label CHEMBL472 ↗ |
| Known as | U-26,452 | ChEMBL registry synonym — accepted as the source's own label CHEMBL472 ↗ |
| Action | Inhibit | “Some sulfonylureas, as the glibenclamide, stimulate insulin secretion by binding to SUR1 subunit and closing KATP channels by an ATP-independent mechanism.” NCT00610038 ↗ |
| Modality | Small molecule | “oral sulfonylurea, glyburide” NCT00160485 ↗ |
| Route | Oral | “Women assigned to receive glyburide will begin with 2.5mg orally with the morning meal.” NCT00160485 ↗ |
| Target | ABCC8 | “Several studies have identified heterozygous activating mutations of the coding sequence of KCNJ11 or ABCC8 in patients having a permanent neonatal diabetes mellitus...” NCT00610038 ↗ |